Home › with
 

Keywords :   


Tag: with

Witness to Shooting at Naval Reserve Center Speaks Exclusively with NewsChannel 9

2015-07-23 07:30:16| Apparel - Topix.net

For the first time since Thursday's shooting, Kenneth Toney walks on the riverwalk near the Navy Reserve Center, Wednesday. "Right now I can still see it vividly in my mind, I can still see it in my head," Toney said.

Tags: with center reserve shooting

 

Used Prices Holding Up Pretty Well Even with Rising Supply

2015-07-23 07:22:08| AutomotiveDigest.com - Automotive Industry News

Jonathan Banks Executive Automotive Analyst NADA Used Car Guide Used vehicle price declines are continuing, but at a more moderate pace. In June, prices of used vehicles up to eight years in age fell by 2.5% from May, or more than a half-percentage point less than the 3.2% drop recorded a month earlier. Looking at […] The Article Used Prices Holding Up Pretty Well Even with Rising Supply appeared first on Automotive Digest.

Tags: with prices supply pretty

 
 

Witness to Shooting at Naval Reserve Center Speaks Exclusively with NewsChannel 9

2015-07-23 06:57:00| Footwear - Topix.net

For the first time since Thursday's shooting, Kenneth Toney walks on the riverwalk near the Navy Reserve Center, Wednesday. "Right now I can still see it vividly in my mind, I can still see it in my head," Toney said.

Tags: with center reserve shooting

 

FCC to AT&T: We'll OK DirecTV Deal With These Conditions

2015-07-22 18:04:07| PC Magazine Software Product Guide

Chairman Tom Wheeler circulated a proposal that would allow AT&T to acquire DirecTV, with some restrictions.

Tags: with conditions deal att

 

European Commission Approves Mercks Anti-PD-1 Therapy, KEYTRUDA (pembrolizumab), for Both First-line and Previously-treated Patients with Advanced Melanoma

2015-07-22 13:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KEYTRUDA Demonstrated Superior Survival versus Ipilimumab in a Phase 3 Clinical Trial KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of advanced (unresectable or metastatic) melanoma in adults. The European Commission approval of KEYTRUDA is based on data from three clinical studies conducted in more than 1,500 first-line and previously-treated patients with advanced melanoma. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558orAn Phan, (908) 255-6325orInvestor:Joseph Romanelli, (908) 740-1986orJustin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with advanced european commission

 

Sites : [400] [401] [402] [403] [404] [405] [406] [407] [408] [409] [410] [411] [412] [413] [414] [415] [416] [417] [418] [419] next »